GlaxoSmithKline plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Ms E N Walmsley |
||||
b) |
Position/status |
Chief Executive Officer |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr R G Connor |
||||
b) |
Position/status |
President, Global Vaccines |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr S P Dingemans |
||||
b) |
Position/status |
Chief Financial Officer |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr J Ford |
||||
b) |
Position/status |
SVP & General Counsel |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr J Ford |
||||
b) |
Position/status |
SVP & General Counsel |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||
b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr N Hirons |
||||
b) |
Position/status |
SVP, Global Ethics & Compliance |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr N Hirons |
||||
b) |
Position/status |
SVP, Global Ethics & Compliance |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||
b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr B McNamara |
||||
b) |
Position/status |
CEO, GSK Consumer Healthcare |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||
b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr D Redfern |
||||
b) |
Position/status |
Chief Strategy Officer |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr R Simard |
||||
b) |
Position/status |
President, Pharma Supply Chain |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Ms C Thomas |
||||
b) |
Position/status |
SVP, Human Resources |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr P C Thomson |
||||
b) |
Position/status |
President, Global Affairs |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2018-10-12 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |